Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17272
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBradfield, Nicholas I-
dc.contributor.authorEllis, Kathryn A-
dc.contributor.authorSavage, Greg-
dc.contributor.authorMaruff, Paul-
dc.contributor.authorBurnham, Samantha-
dc.contributor.authorDarby, David-
dc.contributor.authorLautenschlager, Nicola T-
dc.contributor.authorMartins, Ralph N-
dc.contributor.authorMasters, Colin L-
dc.contributor.authorRainey-Smith, Stephanie R-
dc.contributor.authorRobertson, Joanne-
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorWoodward, Michael M-
dc.contributor.authorAmes, David-
dc.date2018-03-20-
dc.date.accessioned2018-03-22T23:32:11Z-
dc.date.available2018-03-22T23:32:11Z-
dc.date.issued2018-07-
dc.identifier.citationAlzheimer disease and associated disorders 2018; 32(3): 190-196-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17272-
dc.description.abstractGiven the long preclinical disease course of Alzheimer disease (AD) pathology, novel treatments may be more efficacious if administered before the emergence of dementia. Thus, accurate prediction of who will develop AD dementia is of key importance in selecting individuals for trials of treatment and may become crucial for future selection of patients for therapy. As part of the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing, 901 individuals who did not have dementia were recruited. We assigned individuals according to Petersen criteria and Winblad criteria for Mild Cognitive Impairment (MCI) at baseline. We then stratified individuals with amnestic MCI into 2 groups according to the severity of their memory impairment on baseline neuropsychological assessment. Incident diagnosis of AD dementia was established by consensus of an expert panel at 36 months. At 36 months, 725 (80.5%) participants were followed up, 54 (7.4%) of whom developed AD dementia. Subjects with amnestic MCI according to Petersen criteria were more likely to develop AD dementia [positive predictive value; PPV, 24.1%; 95% confidence interval (CI), 18.4-30.6] than healthy controls (PPV, 1.0%; 95% CI, 0.3-2.3). Winblad criteria were also effective, with multiple domain amnestic MCI being most accurate at predicting AD dementia (PPV, 47.3%; 95% CI, 33.7-61.2). Finally, more severe amnestic impairment below the median was useful for predicting the development of AD dementia in single domain amnestic MCI (PPV, 28.1%; 95% CI, 17.0-41.5) and in multiple domain amnestic MCI (PPV, 65.7%; 95% CI, 47.8-80.9). Memory impairment per se, impairment in multiple cognitive domains and severity of memory impairment were all associated with greater risk of developing AD dementia in this sample. Characterizing the severity of memory impairment may provide prognostic stratification within Petersen or Winblad taxonomies of amnestic MCI.-
dc.language.isoeng-
dc.titleBaseline Amnestic Severity Predicts Progression From Amnestic Mild Cognitive Impairment to Alzheimer Disease Dementia at 3 Years.-
dc.typeJournal Article-
dc.identifier.journaltitleAlzheimer disease and associated disorders-
dc.identifier.affiliationNorthWestern Mental Health, Melbourne Healthen
dc.identifier.affiliationAcademic Unit for Psychiatry of Old Age, Department of Psychiatry, The University of Melbourne, Kew, Victoria, Australiaen
dc.identifier.affiliationUniversity of Melbourne, St Vincent's Clinical School, St Vincent's Hospital, Fitzroy-
dc.identifier.affiliationAcademic Unit for Psychiatry of Old Age, Department of Psychiatry, The University of Melbourne-
dc.identifier.affiliationARC Centre of Excellence in Cognition and its Disorders, Macquarie University, Sydney, NSW-
dc.identifier.affiliationCogstate Pty Ltd, Melbourne-
dc.identifier.affiliationCSIRO-
dc.identifier.affiliationThe Florey Institute of Neurosciences and Mental Health-
dc.identifier.affiliationCentre of Excellence for Alzheimer's disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Perth, WA, Australia-
dc.identifier.affiliationPET Centre, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Geriatric Medicine, Heidelberg Repatriation Hospital, Austin Health, Heidelberg West, Victoria, Australia-
dc.identifier.affiliationNormanby House, St George's Hospital, Kew, Vic-
dc.identifier.affiliationNational Ageing Research Institute, Parkville-
dc.identifier.doi10.1097/WAD.0000000000000252-
dc.identifier.orcid0000-0003-3910-2453-
dc.identifier.pubmedid29561277-
dc.type.austinJournal Article-
local.name.researcherMasters, Colin L
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.languageiso639-1en-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptAged Care-
crisitem.author.deptGeriatric Medicine-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

46
checked on Oct 4, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.